Table 1: C. albicans ATCC 18804 MIC 0.39 µM.
- Measure
- MIC
- Value
- 0.39 µM
- Target
- Candida albicans
- Assay
- Not reported by source
Pharmaceutics · 2025
Sequence evidence
VGECVRGRCPSGACCSQWGYCGKGPKYCGR
VGECVRGRCPSGACC SQWGYCGKGPKYCGR
Experimental observations
Table 1: C. albicans ATCC 18804 MIC 0.39 µM.
Table 1: C. albicans ATCC 18804 MIC50 0.19–0.39 µM.
Table 1: C. albicans ATCC 18804 MFC 0.78 µM.
Table 1: C. albicans ATCC 10231 MIC 0.78 µM.
Table 1: C. albicans ATCC 10231 MIC50 0.19–0.39 µM.
Table 1: C. albicans ATCC 10231 MFC >6.25 µM.
Table 1: C. albicans ATCC 10231 BIC50 25–50 µM.
Table 1: C. albicans ATCC 10231 BIC 50 µM.
Table 1: C. albicans 8.2 MIC 0.78 µM.
Table 1: C. albicans 8.2 MIC50 0.39 µM.
Table 1: C. albicans 8.2 MFC >6.25 µM.
Table 1: C. albicans 8.2 BIC50 6.25–12.5 µM.
Table 1: C. albicans 8.2 BIC 12.5 µM.
Table 1: C. albicans 9.1 MIC 0.39 µM.
Table 1: C. albicans 9.1 MIC50 0.19–0.39 µM.
Table 1: C. albicans 9.1 MFC 6.25 µM.
Table 1: C. albicans 9.1 BIC50 6.25–12.5 µM.
Table 1: C. albicans 9.1 BIC 50 µM.
Table 1: C. tropicalis v13a4/2 MIC 0.39 µM.
Table 1: C. tropicalis v13a4/2 MIC50 0.09–0.19 µM.
Table 1: C. tropicalis v13a4/2 MFC >12.5 µM.
Table 1: C. krusei 225/2 MIC 0.39 µM.
Table 1: C. krusei 225/2 MIC50 0.09–0.19 µM.
Table 1: C. krusei 225/2 MFC >12.5 µM.
Table 1: C. glabrata 252/2 MIC 0.39 µM.
Table 1: C. glabrata 252/2 MIC50 0.09–0.19 µM.
Table 1: C. glabrata 252/2 MFC >12.5 µM.
Table 2: 150 mM NaCl MIC 6.25 µM.
Table 2: 150 mM NaCl MFC 6.25 µM.
Table 2: 1.25 mM CaCl2 MIC 3.13 µM.
Table 2: 1.25 mM CaCl2 MFC 6.25 µM.
Table 2: 1.25 mM MgCl2 MIC 1.56 µM.
Table 2: 1.25 mM MgCl2 MFC 3.13 µM.
Table 2: 10% FBS MIC 0.78 µM.
Table 2: 10% FBS MFC 0.78 µM.
Table 2: RPMI-1640 MIC 50 µM.
Table 2: RPMI-1640 MFC >50 µM.
Table 2: pH 5.0 MIC 0.39 µM.
Table 2: pH 5.0 MFC 0.78 µM.
Table 2: pH 7.0 MIC 0.39 µM.
Table 2: pH 7.0 MFC 0.78 µM.
Table 4: mAc-AMP2 with 3.25 µM GSH MIC 0.78 µM.
Table 4: mAc-AMP2 with 3.25 µM GSH MFC 1.56 µM.
Table 4: mAc-AMP2 after DTT MIC >12.5 µM.
Table 4: mAc-AMP2 after 99°C MIC 0.78 µM.
Table 4: mAc-AMP2 after 99°C MFC 3.13 µM.
Section 3.7: mAc-AMP2 did not cause lysis of erythrocytes after incubation for 2 h even at the concentration of 100 µM.
Section 3.7: cell viability of approximately 100% was observed even at the peptide concentration of 100 µM in the case of the Caco-2 cell monolayer.
Section 3.7: The absence of cytotoxic effects was also shown for PBMCs at a mAc-AMP2 concentration of 25 µM.
Section 3.3: mAc-AMP2 inhibited adhesion of the clinical isolate 8.2 by 42% at concentration of 1.56 µM.
Section 3.3: mAc-AMP2 inhibited adhesion of the clinical isolate 8.2 by 45% at concentration of 3.13 µM.
Section 3.3: mAc-AMP2 inhibited adhesion of the clinical isolate 8.2 by 81% at concentration of 6.25 µM.
Section 3.3: mAc-AMP2 inhibited adhesion of the clinical isolate 8.2 by 96% at concentration of 12.5 µM.
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.